Back to results
US 10,093,910 B2Granted
Engineered CRISPR-Cas9 nucleases
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
Life of this patent
Estimating the term…
Abstract
Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
Claims30
An isolated Streptococcus pyogenes Cas9 (SpCas9) protein that has at least 95% sequence identity to SEQ ID NO:
- 1, with mutations at one or both of Q695 and Q926, and wherein the protein retains the ability to interact with a guide RNA and target DNA.
Dependencies are inferred from the claim text.